Home FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
 

Keywords :   


FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients

2013-07-01 23:05:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS (raltegravir) Film-coated Tablets, Mercks integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Language:  English Contact:  MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results include study adult

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »